What is Appendicular Lean Mass Index?

Updated October 2026: added current sarcopenia cut-offs, clarified the mixed evidence linking lean mass to mortality, added guidance on tracking lean mass during GLP-1 therapy and fixed outdated links.

Understanding Appendicular Lean Mass Index (ALMI)

As health and fitness assessment evolves, so do the metrics and indexes used to measure and monitor the body. One such metric is the Appendicular Lean Mass Index (ALMI). This article is a practical guide to understanding ALMI, its importance and its application in clinical practice.

What is Appendicular Lean Mass Index (ALMI)?

The Appendicular Lean Mass Index, or ALMI, is a measure derived from the lean mass of the upper and lower extremities. It is calculated by summing the lean mass of the arms and legs, measured in kilograms, and dividing it by height in meters squared (kg/m²):

ALMI = (arm lean mass + leg lean mass, kg) ÷ height (m)²

Because most appendicular lean mass is skeletal muscle, sarcopenia guidelines use the same calculation as a measure of muscle quantity, often under the name appendicular skeletal muscle mass index (ASMI).

Importance of Appendicular Lean Mass Index

ALMI is a useful tool for assessing muscle health, particularly in older adults and populations at risk of sarcopenia, a condition characterized by loss of muscle mass and function with age. By providing an objective measure of muscle quantity, ALMI is an important indicator of overall body composition and physical health, especially when interpreted alongside measures of strength and function.

Appendicular Lean Mass Index and Body Composition

Body composition refers to the proportions of different types of tissue in the body, including fat, muscle and bone. Dual-energy X-ray absorptiometry (DXA) is widely available and is the method most often used to report ALMI in clinical practice. MRI and CT are considered the gold standards for non-invasive assessment of muscle mass, but they are rarely used in primary care because of cost, lack of portability and the need for specialized staff.

With DXA, you can obtain a detailed printout of body composition data, including regional lean mass and ALMI. This information can be valuable for tracking changes in muscle mass over time, especially for athletes, or for monitoring the risk of sarcopenia in older adults.

How to measure the Appendicular Lean Mass

Appendicular Lean Mass (ALM) is typically measured with one of two techniques. Dual-energy X-ray absorptiometry (DXA) uses low-dose X-rays to measure bone density and body composition. Bioelectrical impedance analysis (BIA), used by devices such as InBody, measures the resistance of small electrical currents as they pass through the body. BIA does not measure muscle directly: it estimates muscle mass using equations calibrated against DXA, so results depend on the device and equation used. The European Working Group on Sarcopenia in Older People (EWGSOP2) notes that muscle mass estimates differ across device brands and reference populations, and that BIA prediction equations still need validation in specific populations. Hydration status can also affect both BIA and DXA readings. Whichever method you choose, use the same device and protocol for repeat measurements so changes reflect the patient rather than the method.

Appendicular Lean Mass Index in Health and Fitness Assessment

In health and fitness settings, ALMI can offer valuable insights into an individual's body composition. For example, athletes might use ALMI to track changes in muscle mass over time or to compare their muscle mass with normative values for their sport. Such comparisons can indicate whether an athlete's muscle mass suits the demands of their sport or whether building more muscle should be a focus.

Appendicular Lean Mass Index and Aging

As people age, they tend to lose muscle mass. This loss contributes to the development of frailty and functional impairment in older adults. ALMI helps quantify this muscle loss over time.

Appendicular Lean Mass Index and Mortality Risk

The evidence linking ALMI to mortality is mixed. A 2021 meta-analysis of nine studies of community-dwelling adults aged 65 and older found that people who died during follow-up had, on average, a lower appendicular skeletal muscle mass index than those who survived. However, the Sarcopenia Definition and Outcomes Consortium found that DXA lean mass was not associated with falls, mobility limitation, hip fracture or mortality in community-dwelling older adults, while low grip strength and slow gait speed were. In practice, ALMI is most informative when paired with grip strength and gait speed.

Appendicular Lean Mass Index and Sarcopenia

Sarcopenia is a condition characterized by the loss of muscle mass and function, often associated with aging. Under EWGSOP2, low muscle strength is the key characteristic of sarcopenia, and low muscle quantity is used to confirm the diagnosis. Commonly used cut-offs for low muscle quantity include:

• EWGSOP2 (2019): appendicular skeletal muscle mass index below 7.0 kg/m² in men and below 5.5 kg/m² in women, or absolute appendicular skeletal muscle mass below 20 kg in men and below 15 kg in women.
• Asian Working Group for Sarcopenia (2019): below 7.0 kg/m² in men and below 5.4 kg/m² in women when measured by DXA.

These thresholds were developed for older adults and specific populations, so apply them with care in younger, athletic or non-European and non-Asian patients.

Appendicular Lean Mass Index in Disease States

Apart from aging and fitness assessment, ALMI has applications in various disease states. For instance, cancer patients often experience muscle wasting, and ALMI can be used to track this loss and guide interventions. ALMI can also help assess muscle health in people with obesity, where body weight alone can hide low muscle mass.

Appendicular Lean Mass Index During Weight Loss and GLP-1 Therapy

With the growing use of GLP-1-based medications, lean mass has become a frequent clinical question. Reported lean mass losses in clinical trials of these drugs vary widely, from roughly 15% or less to 40% to 60% of total weight lost. Lean mass measured by DXA includes organs, bone and water, not just muscle, and MRI-based studies suggest that muscle changes with GLP-1 receptor agonists may be largely adaptive. Older age and more severe disease may still raise sarcopenia risk. Measuring ALMI before and during treatment, together with strength testing, helps identify patients who need extra attention to protein intake and resistance training. See also our post on transitioning off GLP-1 medications.

Appendicular Lean Mass Index and Exercise

Exercise, particularly resistance training, is known to increase muscle mass. Tracking changes in ALMI can provide an objective measure of the effectiveness of exercise interventions.

The Future of Appendicular Lean Mass Index

As more research is conducted, the role of ALMI in health and fitness will continue to evolve. Current sarcopenia definitions place more weight on strength and physical performance than on muscle mass alone, and researchers continue to refine how muscle quantity should be measured and interpreted.

Conclusion

The Appendicular Lean Mass Index provides a practical measure of muscle mass and offers valuable insight into an individual's overall health and fitness. Whether you work with athletes, older adults at risk of sarcopenia, or patients on weight loss medications, tracking ALMI alongside strength and function can strengthen your clinical decisions.

Heads Up unifies body composition data from connected devices such as InBody and Withings with labs, wearables and EHR data in one longitudinal record, so you can see ALMI trends in context for every client. Learn more about Heads Up for longevity practices, or see how Heads Up tracks body composition for your clients: request a demo.

References

1. Cruz-Jentoft, A. J., et al. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 48(1), 16-31. PubMed
2. Chen, L. K., et al. (2020). Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. Journal of the American Medical Directors Association, 21(3), 300-307. PubMed
3. Bhasin, S., et al. (2020). Sarcopenia definition: the position statements of the Sarcopenia Definition and Outcomes Consortium. Journal of the American Geriatrics Society, 68(7), 1410-1418. PubMed
4. de Santana, F. M., et al. (2021). Low muscle mass in older adults and mortality: a systematic review and meta-analysis. Experimental Gerontology, 152, 111461. PubMed
5. Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 26(Suppl 4), 16-27. PubMed